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Introduction
Gammadelta (γδ) T lymphocytes contribute to the first-
line defense against several pathogens [1]. Two main 
subsets of γδ T cells are know [2]: Vδ2 T lymphocytes, 
circulating in the peripheral blood, which are involved 
in the response to mycobacteria, coxsakievirus B3 and 
herpes simplex virus type 2 [3, 4]; Vδ1 T cells, which 
are resident in the mucosal-associated lymphoid tissue 
and participate in the immunity against Listeria mono-
cytogenes and cytomegalovirus [5, 6].
In HIV-1 infected patients, Vδ1 T lymphocytes are in-
creased in periphery, as a result of mucosal depletion and 
recirculation [7, 8], whereas circulating Vδ2 T cells may 
decrease possibly due to reduced response to chemo-
tactic stimuli or impaired survival [9, 10].
Both Vδ1 and Vδ2 T cells can produce interferon (IFN)-γ 
in response to damage signals [11]. It has been reported 
that resident γδ T lymphocytes can produce interleukin 
(IL)-17A, crucial for the control of intracellular patho-
gens and fungi [12].
Recently, we described in HIV-1 infected patients the 
expansion of a γδ T cell subset responsive to Ca and both 
IFN-γ and IL-17A-producing [13]. Moreover, in the 
presence of IL-23, IL-6 and transforming growth factor 
(TGF)-β, a subset of Vδ2 T lymphocytes can produce 
another mediator reported to contribute to Ca immunity 
in humans that is IL-22, besides IL-17A. On the other 
hand, sera levels of IL-22 are inversely correlated to the 
replication in vitro of HIV-1 subtype C, that accounts for 
50% of all HIV-1 infections worldwide [14].
HIV-1-positive subjects represent a category of at-risk 
individuals due to their impaired immune responses; 
therefore influenza vaccination is recommended in or-
der to reduce the risk of respiratory threatening com-
plications. However, the immune response to influenza 
vaccines can be suboptimal or very low depending on 
their immunodeficient status. To fill this gap, vaccines 
containing adjuvants, such as the oil-in-water emulsion 
MF59, have been investigated and largely used in Eu-
rope since 1997, demonstrating a good safety profile 
and a higher immunogenicity than conventional non-
adjuvanted vaccines, particularly in immunosuppressed 
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Summary
Introduction. We previously reported that in HIV-1 infected 
patients circulating Vdelta1 T lymphocytes (Vδ1) increase and 
proliferate in vitro in response to Candida albicans (Ca). Herein, 
we analysed the effects of MF59 adjuvant on the Vδ1 T cell 
responses to hemagglutinin (HA) and Ca in HIV-1 seropositive 
and seronegative adults after influenzal vaccine, to clarify the 
molecular mechanisms triggered in vivo by an adjuvanted vac-
cine against influenza virus.
Materials and methods. 58 seropositive (HIV-1+) and 48 seron-
egative (HIV-1-) subjects received influenzal vaccines containing 
or not the MF59 adjuvant. The follow-up of in vitro T cell pro-
liferation and cytokine production (IL-17A, IL-22, IL-23, IL-6) 
to HA and Ca antigens were performed at different time points 
(at basal time and after 30 and 90 days from vaccination) by 
cytofluorimetric approaches.
Results. We confirmed that in HIV-1 infected individuals the Vδ1 
T cell subset is expanded in HIV-1 infected individuals and moreo-
ver the number of circulating Vδ1 T cells significantly enhanced in 
all HIV-1+ subjects on day 90 after influenza vaccination. Regard 
the follow-up of proliferative responses, the increments of CD3+ 
response to HA and Vδ1 T cells to Ca in HIV-1+ individuals were 
detectable earlier on day 30 for MF59-vaccinated patients, instead 
on day 90 post-vaccination in HIV+-vaccinated without MF59 adju-
vant. Of note, production of IL-17A and IL-22, two cytokines with 
anti-fungal activity, in response to Ca was enhanced (for IL-17A) 
or restored (for IL-22) by vaccination in HIV-1+ donors, mainly 
using the MF59-adjuvanted vaccine. Moreover, after vaccination 
IL-23 and IL-6 production increased in response to HA in the HIV+ 
and HIV- groups vaccinated with MF59 adjuvant.
Conclusions. We suggest that in HIV-1 infected patients the cir-
culating Vδ1 T lymphocytes reactive to Ca upon challenge with 
influenza virus vaccine receive an activating/enhancing signal 
mediated by cytokines triggered by the boost with HA antigen 
particularly in presence of MF59 adjuvant.
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patients. In the last years, safety and immunogenicity 
of the MF59-adjuvated vaccine has been proved also in 
HIV-1 seropositive individuals [15]; nevertheless, the 
molecular mechanisms triggered in vivo by MF59, that 
enhances T cell specific response to hemagglutinin (HA), 
the major antigen of influenza virus, is still not fully un-
derstood, in particular in HIV-1-positive subjects.
In this paper we show that the influenza vaccine con-
taining the MF59 adjuvant influences the function of 
Vδ1 T lymphocytes in HIV-1 seropositive patients. 
Moreover, we observe an enhancement of cytokine 
production, including IL-17A and IL-22, in response 
to Ca, and IL-23 or IL-6 in response to HA, upon in-
fluenza virus vaccination with a vaccine containing 
the MF59 adjuvant.
Materials and methods
Study design, subjects and vaccination
58 seropositive (HIV-1+) and 48 seronegative (HIV-1-) 
subjects were enrolled for influenza virus vaccination 
at the Rehabilitation Centre of San Patrignano (Rimini, 
Italy), provided informed consent and ethics committee 
approval of San Martino Hospital (EUDRACT code: 
2006-001103-11). Both HIV-1+ and HIV-1- subjects, 
randomly assigned to group A or B, receive intramus-
cularly a single dose of an influenza virus vaccine with 
MF59 adjuvant (Fluad, n = 29 HIV-1+, n = 24 HIV-1-) 
or a subunit vaccine (AgrippalS1, n = 29 HIV-1+, 
n = 24 HIV-1-), respectively (both from Novartis Srl). 
The vaccines contained 15 µg of HA from A/New 
Caledonia/20/99 (H1N1), A/California/7/2004 (H3N2) 
and B/Shangai/361/2002 influenza virus. Blood sam-
ples were collected before vaccination (time 0) and at 30 
or 90 days postvaccination (time 30 and time 90). The 
characteristics of HIV-1+ and HIV-1- subjects are sum-
marized in Table I.
Phenotypic analysis
The absolute number (cells/µl) of peripheral T-lym-
phocyte subsets were performed in HIV-1+ subjects at 
study entry and at 30 or 90 days postvaccination in sin-
gle platform using a commercially available kit (Multi-
set, Becton Dickinson, BD). The frequencies of circulat-
ing γδT cell populations were evaluated with the anti-
Vδ1 mAb A13 and the anti-Vδ2 mAb BB3 (both IgG1), 
labelled with the fluorochrome Alexafluor594 prepared 
as described by manufacturer’s instructions (Zenon La-
beling Kit for mouse IgG1, Molecular Probes) and al-
lophycocyanin-conjugated (APC) anti-CD3 mAb (BD). 
The percentage of γδ positive T cells was normalized 
for the T cell count in blood and expressed as number 
of cells/µl.
Proliferation assay
The proliferation of pheripheral lymphocytes to purified 
HA antigens (kindly supplied by Novartis Vaccines Srl) 
and Ca bodies was evaluated by a dye dilution assay [15]. 
Briefly, peripheral blood mononuclear cells (PBMC), 
obtained from Ficoll-Hypaque (Biochrom) gradient of 
heparinized venous blood, were stained with the car-
boxy-fluorescein diacetate succinimidyl ester (CFSE, 
Sigma Chemicals Co.) and seeded at 4 × 10^5/200 µl 
per well in duplicate in a flat-bottomed microtitre plate 
containing 20 µl of antigens (HA or Ca) in complete 
medium composed of RPMI1640 (Biochrom) with 10% 
autologous plasma. HA was used at 2 or 6 µg/ml final 
concentration; Ca was grown in RPMI 1640 medium for 
2 days, washed twice in PBS, autoclaved and used at 
106 bodies/ml final concentration in culture (body/cell 
ratio: 1/1). These concentrations, in preliminary titra-
tions experiments, were optimal for PBMC stimulation. 
After 10 days (the last 7 days with IL-2), the cells were 
stained with Alexafluor594-A13 or Alexafluor594-BB3, 
followed by the allophycocyanin-conjugated (APC) 
anti-CD3 mAb (BD) and acquired by flow cytometry. 
Data were analysed on a FACS Canto cytometer (BD) 
using FACS DIVA software. Gates were set on live lym-
phocytes according to forward scatter and side scatter 
characteristics, 50,000 CD3+ T cells were collected for 
each sample. To estimate the frequency of proliferating 
cells (precursor frequency) in response to antigens, flow 
cytometric data files were analyzed with the “Prolifera-
tion Wizard” module using the ModFit LT version 3.0 
computer program (Verity Software House Inc.).
Cytokine measurement
Human IL-17A, IL-22, IL-23, IL-6 cytokines were 
measured in harvested supernatants (SN) before IL-2 
adding, using the FlowCytomix Multiplex kit and BMS 
FlowCytomix software (Bender MedSystem), following 
manufacturer’s instructions. Results are expressed as pg/
ml for each cytokine.
Tab. I. Characteristics of hiv-1 seropositive and seronegative subjects.
HIV-1+ HIV-1-
Characteristics
(at time 0)1
Group A (Fluad)
(n = 29)
Group B (Agrippal)
(n = 29)
Group A (Fluad)
(n = 24)
Group B (Agrippal)
(n = 24)
age (mean ± sd) 31.4 ± 7.2 33.6 ± 6.9 39.4 ± 5.6 38.6 ± 6.3
sex 19m, 10f 20 m, 9f 10m, 14f 9m, 15f
hiv-1 rna copies/ml 2,607 ± 2,480 1,795 ± 1,610 na2 na2
Cd4+ cells/mm3
Cd4/Cd8 ratio
371 ± 114
0.47 ± 0.18
284 ± 105
0.56 ± 0.19
na2 na2
haart3 20/29 18/29 na2 na2
1 viremia and Cd4+ cell count did not vary significantly at time 30 or time 90 after vaccination; 2 na: not applicable; 3 haart: highly active antiretroviral 
therapy.
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pointed out their response to Ca in vitro [13], we moni-
tored the effect of influenza virus vaccination on Vδ1 pro-
liferation to relevant antigen as HA and to fungal antigen 
as Ca (Fig. 2). The data showed a significantly higher Vδ1 
proliferating precursor frequency (f) in response to Ca in 
HIV-1+ than in HIV-1- individuals already at time 0 (mean 
f 0.0045 vs. 0.0019); nevertheless, we observed postvacci-
nation an increment of in vitro Ca-specific reactivity more 
efficiently from HIV-1+ subjects receiving MF59-adju-
vanted vaccine, whereas only a slight effect was observed 
in HIV-1- subjects. Of note, the Ca-specific increment of 
Vδ1 T cells was faster in HIV-1+ subjects MF59-threated 
than HIV-1+ subjects immunized without adjuvant, that is 
the proliferative kinetic was similar to HA-specific trend 
evaluated in all the CD3+ αβ T cells of HIV-1+ patients 
immunized by Fluad [15]. The Vδ1 T cell response to HA 
was undetectable and superimposable to that of unstimulat-
ed cells, either in HIV-1+ or in HIV-1- individuals (Fig. 2, 
panel A and B for HIV-1+, panel A and B for HIV-1-). No 
significant proliferation of Vδ2 T cells to either Ca or HA 
was observed in all the vaccinated groups.
IL-17A and IL-22 production to Ca increase after MF59-
adjuvanted vaccination in HIV-1+ subjects.
We and others described that in particular Vδ1 T cells 
produced IL-17A in HIV-1-infected patients [13], 
while their IL-22 production is deficient [14]. Thus, we 
monitored the influence of vaccination on cytokine re-
Statistical analysis
Statistical analysis was performed by the “analysis of 
the variance” (ANOVA) for repeated measures. We 
have first analysed the variance of each parameter in the 
HIV+ group, and then we have compared both HIV+ and 
HIV- groups. The cut-off value of significance was .01.
Results
Circulating Vδ1 T cell number in HIV-1+ subjects in-
creases after influenza vaccination. Pheripheral blood 
phenotypes, performed before vaccination (time 0) and 
at 30 or 90 days postvaccination, didn’t show significant 
change for CD4+ and CD8+T subsets in HIV+ patients 
during the follow-up [15], but confirmed our previous 
observations [14] regard to γδ T cells. In fact the number 
of Vδ1 T lymphocyte resulted significantly higher in 
all HIV-1+ subjects than in HIV-1- donors (p < 0.01) at 
basal time, at variance with Vδ2 T cells. Moreover the 
follow-up after influenza vaccination showed a signifi-
cant enhancement of the Vδ1 circulating T cell subset in 
both HIV-1+ groups (vaccinated with or without MF59) 
on day 90. No variations of the Vδ2 T cell population 
in peripheral blood was observed at any time in either 
HIV-1+ or HIV-1- donors (Fig. 1).
Vδ1 T cell reactivity to C. albicans (Ca) increases in 
HIV-1+ subjects immunized with MF59-adjuvanted in-
fluenza vaccine.
Since we reported that circulating Vδ1 in HIV-1-infected 
patients are expanded in vivo and previously we have been 
Fig. 1. increase of vδ1 circulating t cells in hiv-1+ subjects upon 
influenza virus vaccination with (panel a) and without mf59 (pan-
el C) adjuvant. the absolute number of δγ t cells was normalized 
for tCd3+ count in blood samples collected before vaccination 
(time 0) and at 30 and 90 days postvaccination (time 30 and 90).
* p ≤ 0.001 vs. hiv-1-, ** p ≤ 0.001 vs. t0. 
Fig. 2. follow-up of in vitro proliferative response of vδ1 t cells 
to Ca and ha in hiv-1+ and hiv-1- subjects vaccinated by fluad or 
aggrippal influenza virus vaccine.
pbmC were isolated before (time 0) and 30 or 90 days after vaccination 
from either seropositive (hiv-1+, panel a with mf59 adjuvant and pan-
el b without mf59) or seronegative (hiv-1-, panel C with mf59 adjuvant 
and panel d without mf59) and evaluated for proliferating activity in 
vitro to Ca and ha antigens by dye dilution assay. the results were ex-
pressed as proliferating precursor frequency by computeri-zed analy-
sis with the modfit program. none: pbmCs cultured in the absence 
of antigen. mean ± sd from 29 hiv-1+ subjects, panels a and C, or 24 
hiv-1- subjects, panels b and d. * p ≤ 0.001 vs. hiv-1-, ** p ≤ 0.001 vs. t0 
and p ≤ 0.001 fluad vs. agrippals1. 
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lease induced by HA and Ca-stimulation in culture sur-
natants (SN) on day 3 harvested before (time 0) and 30 
or 90 days after vaccination. First, we confirmed that 
in HIV-1+ individuals IL-17A production in response 
to Ca is stronger than in HIV-1- donors and detectable 
already at time 0 (Fig. 3, panel A vs. B, mean 400 pg/
ml vs. 200 pg/ml). Second, in HIV-1+ subjects (Fig. 3, 
panel A) but not in HIV-1- donors (Fig. 3, panel B), 
Fluad vaccine enhanced this response significantly 
(> 1000 pg/ml at day 30 and 90 vs. 400 pg/ml). Also 
in this case the non-adjuvanted vaccine AgrippalS1 did 
not influence the IL-17A release in HIV-1+ patients 
(Fig. 3, panel A). No IL-17A production was observed 
in response to HA, both in HIV-1+ subjects (Fig. 3, 
panel A) and in HIV-1- donors (Fig. 3, panel B), re-
gardless the type of vaccine used.
With regard to IL-22, its production Ca-induced was 
deficient in HIV-1+ subjects (Fig. 3, panel C, about 
2000 pg/ml) compared with HIV-1- donors (Fig. 3, pan-
el D, about 6000 pg/ml). However, influenza vaccine 
administration restored an efficient production of IL-22 
to Ca already at 30 days, with a significantly higher effi-
ciency of the MF59-adjuvanted vaccine (Fig. 3, panel C, 
mean 10000 pg/ml at day 30 after Fluad vs. 6000 pg/
ml after AgrippalS1) that enhanced the amount of IL-
22 secreted also in comparison to that of HIV-1- indi-
viduals (Fig. 3, panel C vs. panel D, mean 10000 pg/ml 
vs. 8000 pg/m at day 30). No significant IL-22 produc-
tion was detected in response to HA, either in HIV-1+ 
subjects (Fig. 3, panel C) or in HIV-1- donors (Fig. 3, 
panel D), regardless the vaccine administered.
IL-23 and IL-6 production in response to HA is enhanced 
after administration of MF59-adjuvanted influenza vac-
cine.
We evaluated the release in SN of IL-23 and IL-6 cy-
tokines, required for IL-17A and IL-22 synthesis, be-
fore (time 0) and 30 or 90 days postvaccination upon 
stimulation with Ca or HA as above. Both in HIV-1+ and 
in HIV-1- subjects administration of MF59 adjuvanted 
vaccine led to an significant enhancement of IL-23 pro-
duction in response to HA, detectable at day 30 and 90 
(Fig. 4, panels A and B), the effect being more evident 
in HIV-1+ individuals. Interestingly, also for the HIV-1+ 
and in HIV-1- Fluad groups, the IL-6 synthesis was in-
creased in HA-stimulated cultures upon influenza vac-
cination (Fig. 4, panels C and D). Moreover, IL-6 pro-
duction was increased also in response to Ca in HIV-1+ 
donors receiving adjuvanted vaccine (Fig. 4, panel C).
Discussion
In this paper we show that: i) the influenza vaccine in 
HIV-1 seropositive individuals induce in vivo expan-
sion of Vδ1 T lymphocytes that in vitro proliferate to 
Ca; ii) regard to cytokine studies, the MF59 adjuvanted 
vaccine influence more efficiently the cytokine profile 
in response to Ca (for IL-17A and IL-22) and to HA (for 
IL-23 or IL-6) in HIV-1+ subjects.
It is well known that the CD4 T helper subset is highly 
impaired in HIV-1-infected patients, leading to a defec-
tive control of viral infection and to an increased sus-
ceptibility to fungi and intracellular pathogens evasion. 
From this viewpoint, influenza vaccination should re-
duce the risk of respiratory threatening complications.
The availability of an adjuvanted vaccine, that enhances 
the immunogenicity of influenza virus vaccines, led to 
the possibility to administrate this vaccine in immuno-
Fig. 4. il-23 and il-6 production in response to Ca and ha in 
hiv-1+ and hiv-1- subjects increases upon administration of in-
fluenza vaccine.
pbmC, isolated at time 0 and 30 or 90 days postvaccination, were cul-
tured in the presence of Ca or ha and supernatants were harvested on 
day 3. il-23 (panels a and b) and il-6 (panels C and d) cytokines were 
measured by flowCytomix multiplex Kit and the results expressed as 
pg/ml for each cytokine. hiv-1+ subjects panels a and C; hiv-1- sub-
jects panels b and d. fluad, with mf59, black symbols in each panel. 
agrippals1, wo mf59, white symbols in each panel. * p ≤ 0.001 vs. hiv-
1, ** p ≤ 0.001 vs. t0. 
Fig. 3. il-17a and il-22 synthesis to Ca are higher upon influenza 
vaccination.
pbmC, isolated at time 0 and 30 or 90 days postvaccination, were cul-
tured in the presence of Ca or ha and supernatants were harvested on 
day 3. il-17a (panels a and b) and il-22 (panels C and d) cytokines were 
measured by flowCytomix multiplex Kit and the results expressed as 
pg/ml for each cytokine. hiv-1+ subjects panels a and C; hiv-1- sub-
jects panels b and d. fluad, with mf59, black symbols in each panel. 
agrippals1, wo mf59, white symbols in each panel. * p ≤ 0.001 vs. hiv-
1, ** p ≤ 0.001 vs. t0. 
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deficient subjects, such as HIV-1+ individuals, reaching 
a good immune response. We previously found that in-
fluenza virus vaccination triggers a specific response in 
both HIV-1+ and HIV-1- individuals; of note, the kinetic 
and intensity by CD3+T cells were significantly more 
faster in HIV-1+ subjects treated with MF59-adjuvanted 
vaccine [15]. These data were confirmed in this report by 
the analysis of release of IL-23 and IL-6 cytokines to HA. 
Both of the inflammatory mediators are required for the 
production and release of IL-17A, important cytokine in 
the control of fungal infections, by recruiting neutrophils 
and macrophages to infected tissues. Along this line, up-
on vaccination IL-17A production to Ca by lymphocytes 
from HIV-1+ subjects was increased, in particular when 
the MF59-adjuvanted vaccine was used. With regard to 
IL-22, another anti-fungal cytokine, its deficient produc-
tion in cultures stimulated with Ca from HIV-1+ subjects, 
was restored early after influenza vaccine administration, 
at significantly higher level by MF59-adjuvanted vaccine. 
We recently described in HIV-1 infected patients the ex-
pansion of a population of γδ T cells that respond to Ca 
and produce IL-17A, that might participate to anti-fungal 
immune response in vivo [13]. To date several evidences 
strongly suggest that IL-17A and IL-22 cytokines have a 
critical role in mucosal immunity to many extracellular 
pathogens and can also coordinate adaptive immunity to 
some intracellular pathogens. To this issue we confirmed 
a higher number of circulating Vδ1 T lymphocytes in 
HIV-1+ subjects before influenza vaccination, compared 
to healthy donors, that furtherly increases at 90 days 
postvaccination. Interestingly, we observed that Vδ1 
T lymphocytes from HIV-1+ patients proliferate in vitro 
to Ca more efficien-tly after influenza vaccination than 
HIV-1 infected individuals, mainly with MF59-adjuvan-
ted vaccine. Thus, it is tempting to hypothesize that the 
vaccine equipped with the adjuvant is able to overcome 
the hyporesponsiveness of CD4+ T cells in immunosup-
pressed HIV-1+ infected subjects, leading to release of 
cytokines needed for the development of cells producing 
anti-fungal cytokines, possibly represented by a subset 
of γδ T cells. The effector molecules IL-17A, IL-17F and 
IL-22 are produced by a third lineage of CD4+ Th cells 
(Th17), but can be produced also by γδ T cells. Human 
memory Th17 cells were found to react against Ca, and 
they also produce IL-22; recent data suggest that Th17 
subset is impaired in immunosuppressed individuals.
Thus the expansion of a specific circulating γδ T cell 
population, capable of producing anti-fungal cytokines, 
enhanced by influenza vaccine administration, in HIV-1 
infected subjects might participate in to the control of 
HIV-1 spreading and to the defence against opportun-
istic infections, possibly contributing to compensate the 
impairment of CD4+ T cells (Fig. 5).
Fig. 5. work hypothesis.
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